Glasdegib plus low-dose cytarabine for acute myeloid leukemia: Practical considerations from advanced practitioners and pharmacists

OBJECTIVE: Acute myeloid leukemia (AML) is primarily a disease of older adults. These patients may not be candidates for intensive treatment, and there has been an ongoing need for treatment options for this group. We review the use of glasdegib, a hedgehog-pathway inhibitor available for use in com...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:J Oncol Pharm Pract
Main Authors: Relias, Valerie, McBride, Ali, Newman, Matthew J, Paul, Shilpa, Saneeymehri, Seyyedeh, Stanislaus, Genique, Tobin, Jennifer, Hoang, Caroline J, Ryan, Joanne C, Galinsky, Ilene
Formato: Artigo
Idioma:Inglês
Publicado: SAGE Publications 2020
Assuntos:
Review Articles
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC8008421/
https://ncbi.nlm.nih.gov/pubmed/33215562
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1078155220973737
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares